Get the Stockscreener App
54.28
0.63%
0.34
Akero Therapeutics Inc stock is traded at $54.28, with a volume of 1.47M.
It is up +0.63% in the last 24 hours and up +29.18% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$53.94
Open:
$54.24
24h Volume:
1.47M
Relative Volume:
1.04
Market Cap:
$3.96B
Revenue:
-
Net Income/Loss:
$-269.44M
P/E Ratio:
-14.47
EPS:
-3.75
Net Cash Flow:
$-262.63M
1W Performance:
+9.33%
1M Performance:
+29.18%
6M Performance:
+74.48%
1Y Performance:
+154.48%
1-Day Range:
$54.13
$55.87
1-Week Range:
$48.65
$55.87
52-Week Range:
$20.64
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
54.28 | 3.96B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
Day 7 of Gains Streak for Akero Therapeutics Stock with 20% Return (vs. 95% YTD) [6/6/2025] - Trefis
Patrick Lamy Sells 4,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect - ACCESS Newswire
Ameriprise Financial Inc. Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
15,172 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Ameriprise Financial Inc. - MarketBeat
Bank of America Corp DE Lowers Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics Elects New Directors at Annual Meeting - TipRanks
Two Sigma Advisers LP Acquires 27,200 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Bank of America Corp DE Has $1.84 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics Brings Breakthrough Metabolic Disease Pipeline to Goldman Sachs Healthcare Conference - Stock Titan
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Acquired by Two Sigma Investments LP - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Trading 4.5% HigherStill a Buy? - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by BNP Paribas Financial Markets - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
2025-06-01 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation | NDAQ:AKRO | Press Release - Stockhouse
Nuveen Asset Management LLC Sells 3,385 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
How to Take Advantage of moves in (AKRO) - news.stocktradersdaily.com
Akero Therapeutics (NASDAQ:AKRO) Price Target Raised to $64.00 - MarketBeat
ProShare Advisors LLC Has $623,000 Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Buy" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Akero Therapeutics Inc. Stock Jumps Over 4%: What’s Powering This Biotech Surge? - Daily Chhattisgarh News
Akero Therapeutics (AKRO) Stock Climbs: Dissecting the Rally and What Lies Ahead - Daily Chhattisgarh News
2025-05-29 | Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation | NDAQ:AKRO | Press Release - Stockhouse
BNP Paribas Financial Markets Sells 12,220 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics (NASDAQ:AKRO) Shares Down 5.9% Following Insider Selling - MarketBeat
D. E. Shaw & Co. Inc. Sells 89,573 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Woodline Partners LP Grows Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Akero Therapeutics Readies Major Pipeline Updates for Jefferies Healthcare Conference Next Week - Stock Titan
BofA Adjusts Akero Therapeutics (AKRO) Price Target to $64 | AKR - GuruFocus
Akero Therapeutics (NASDAQ:AKRO) Price Target Raised to $64.00 at Bank of America - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Akero Therapeutics (AKRO) Price Target Raised by B of A Securities | AKRO Stock News - GuruFocus
BofA Adjusts Akero Therapeutics (AKRO) Price Target to $64 | AKRO Stock News - GuruFocus
Rafferty Asset Management LLC Sells 17,797 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 637 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
2025-05-25 | Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:AKRO | Press Release - Stockhouse
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Rating of “Buy” from Brokerages - Defense World
D. E. Shaw & Co. Inc. Decreases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Tema Etfs LLC Makes New $894,000 Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics (AKRO) Considers Potential Sale Amid Strategi - GuruFocus
Akero Therapeutics (AKRO) Considers Potential Sale Amid Strategic Interest | AKRO Stock News - GuruFocus
Deutsche Bank AG Has $7.62 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by RTW Investments LP - MarketBeat
Akero: FGF21 Advancement For MASH Targeting Presses On With Key Developments (NASDAQ:AKRO) - Seeking Alpha
Why Akero Therapeutics, Inc. (AKRO) Skyrocketed Today - Insider Monkey
Akero Therapeutics (AKRO) Weighs Sale Amid Takeover Interest - GuruFocus
Akero Therapeutics (AKRO) Considers Potential Sale Following Int - GuruFocus
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):